LadRx (STU:CX5) Institutional Ownership : 0.00% (As of May. 16, 2024)

View and export this data going back to 1986. Start your Free Trial

What is LadRx Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, LadRx's institutional ownership is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, LadRx's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, LadRx's Float Percentage Of Total Shares Outstanding is 98.02%.

LadRx Institutional Ownership Historical Data

The historical data trend for LadRx's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LadRx Institutional Ownership Chart

LadRx Historical Data

The historical data trend for LadRx can be seen below:

	2021-08-31	2021-09-30	2021-10-31	2021-11-30	2021-12-31	2022-01-31	2022-02-28	2022-03-31	2022-04-30	2022-05-31
Institutional Ownership	0.03	0.03	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01

LadRx Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

LadRx (STU:CX5) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LadRx Corp (STU:CX5) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

LADX:USA

Address

11726 San Vicente Boulevard, Suite 650, Los Angeles, CA, USA, 90049

Website

https://www.ladrxcorp.com

LadRx Corp operates as a biopharmaceutical research and development company in the healthcare sector of the United States. It is focused on the discovery, research, and clinical development of novel anti-cancer drug candidates that employ novel linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor. The company develops Aldoxorubicin, which is meant to cure soft tissue sarcoma, a kind of tumor. It also develops Arimoclomol which is in development in Niemann Pick disease Type C (NPC) and Gaucher disease.

LadRx (STU:CX5) Headlines

No Headlines